FDA Formally Rescinds Laboratory Developed Test Rule Following Court Defeat
核心洞察
The FDA has officially rescinded the Laboratory Developed Test (搜索) (LDT) Final Rule on August 6, 2025, following its earlier vacation by a U.S. District Court in Texas.
The rescission removes nine key words from FDA regulations that would have classified laboratories as device manufacturers subject to FDA oversight.
Industry observers speculate the FDA may shift regulatory focus toward Research Use Only (RUO) products as an alternative approach to diagnostic oversight.
The U.S. Food and Drug Administration has formally rescinded the Laboratory Developed Test (搜索) (LDT) Final Rule following its defeat in federal court, marking a definitive end to the agency's controversial attempt to expand regulatory oversight of diagnostic testing performed within individual laboratories.
On August 6, 2025, the Office of Information and Regulatory Affairs (搜索) (OIRA) published a notice confirming that the FDA has rescinded the LDT Final Rule, which was previously vacated by the U.S. District Court for the Eastern District of Texas (搜索) earlier this year. The rescission is currently pending regulatory review by OIRA pursuant to Executive Order 12866.
Regulatory Definition Changes
The rescission will remove nine critical words that the LDT Final Rule had added to the definition of "in vitro diagnostic products" in 21 C.F.R. § 809.3. The rule had stated that IVD products are FDA-regulated devices "including when the manufacturer of these products is a laboratory," effectively bringing laboratory-developed tests under the same regulatory framework as commercially distributed diagnostic devices.
This regulatory language was central to the FDA's strategy to assert jurisdiction over LDTs, which are tests developed and used within individual laboratories rather than distributed commercially. Historically, the agency exercised enforcement discretion over LDTs, allowing laboratories to operate without requiring premarket approval or clearance.
Shift in Regulatory Focus
While the FDA retreats from LDT regulation, industry observers are questioning whether this move could lead to increased scrutiny of Research Use Only (RUO) products. These tools and reagents are labeled for research purposes but are sometimes used in clinical settings, creating potential regulatory gaps.
Experts note that heightened attention on RUO products could indicate an effort by the agency to address concerns about their misuse in diagnostic applications without directly targeting LDTs themselves. This potential shift represents a different regulatory approach that could still allow the FDA to maintain some oversight of laboratory testing practices.
Industry Implications
The FDA's decision follows years of debate surrounding the agency's authority to regulate LDTs under existing medical device laws. The regulatory change raises questions about how laboratories and manufacturers will adapt to evolving oversight priorities, particularly as the distinction between research and clinical use of diagnostic tools becomes increasingly blurred.
The FDA has not yet clarified whether additional guidance or enforcement measures related to RUO products will follow this decision, leaving the industry to navigate an uncertain regulatory landscape in the wake of the LDT rule's formal rescission.